agreed. i got a fright when i saw this aftermarket but looks like good progress on all fronts. For me, at this market cap, the phase 3 study with statistically robust efficacy from phase 2 is the main game. no brainer really.
seems like lots of really interesting stuff happens during the quarter that other biotechs would announce as material events.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TRP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
-0.050(11.6%) |
Mkt cap ! $22.97M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 42.0¢ | 35.0¢ | $929.9K | 2.389M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 74487 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 1426 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| TRP (ASX) Chart |